Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: Mismatch repair-deficient (MMRd) cancers have varied responses to immune-checkpoint blockade (ICB). We conducted a phase II clinical trial of the PD-1 inhibitor pembrolizumab in 24 patients with MMRd endometrial cancer (NCT02899793). Patients with mutational MMRd tumors (6 patients) had higher response rates and longer survival than those with epigenetic MMRd tumors (18 patients). Mutation burden was higher in tumors with mutational MMRd compared with epigenetic MMRd; however, within each category of MMRd, mutation burden was not correlated with ICB response. Pretreatment JAK1 mutations were not associated with primary resistance to pembrolizumab. Longitudinal single-cell RNA-seq of circulating immune cells revealed contrasting modes of antitumor immunity for mutational versus epigenetic MMRd cancers. Whereas effector CD8+ T cells correlated with regression of mutational MMRd tumors, activated CD16+ NK cells were associated with ICB-responsive epigenetic MMRd tumors. These data highlight the interplay between tumor-intrinsic and tumor-extrinsic factors that influence ICB response.
Significance: The molecular mechanism of MMRd is associated with response to anti-PD-1 immunotherapy in endometrial carcinoma. Tumors with epigenetic MMRd or mutational MMRd are correlated with NK cell or CD8+ T cell-driven immunity, respectively. Classifying tumors by the mechanism of MMRd may inform clinical decision-making regarding cancer immunotherapy. This article is highlighted in the In This Issue feature, p. 247.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905265 | PMC |
| http://dx.doi.org/10.1158/2159-8290.CD-22-0686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Pathways and Biomarkers in Endometrial Carcinoma: Paving the Way for Precision Medicine.
Anticancer Agents Med Chem
August 2025
Department of Chemistry, Constituent Government College (M.J.P.R.U. Bareilly), Hasanpur, Uttar Pradesh, 244241, India.
Endometrial carcinoma (EC) is one of the most prevalent gynecological malignancies, with an increasing incidence globally. This review explores the role of molecular markers in revolutionizing the diagnosis, prognosis, and management of EC. This article provides an overview of endometrial carcinoma, emphasizing its subtypes and the molecular mechanisms driving disease progression.
View Article and Find Full Text PDFInduction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer.
Cancer Cell
July 2025
Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:
Mismatch repair deficient (MMRd) tumors harbor thousands of somatic mutations enriched for insertion-deletion (indels) conferring high sensitivity to immunotherapy. We sought to reproduce this phenotype using mutagenic agents to engineer an MMRd genotype in immunoresistant cells. The combination of temozolomide (TMZ) and cisplatin led to a rapid accumulation of a high mutational load enriched for indels in murine cell lines resulting from the epigenetic loss of Msh2.
View Article and Find Full Text PDFComprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer.
ESMO Open
June 2025
Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:
Background: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy, referred to as molecular/minimal residual disease (MRD), is prognostic of disease recurrence in early-stage breast cancer (EBC). Tumor-agnostic approaches that rely on mutation-based assessment in fixed panels of common cancer driver genes have shown limited utility for detecting MRD in EBC. Methylation-based MRD (mMRD) may overcome the limitations of genomic-based MRD (gMRD), though limited clinical validation is available.
View Article and Find Full Text PDFAssociation of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
Gynecol Oncol
June 2025
Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr., Pleasanton, CA 94588, United States.
Objectives: To evaluate associations between epigenetic mismatch repair deficiency (MMRd), clinicopathologic factors and overall survival in a diverse endometrial cancer cohort.
Methods: Retrospective analysis of patients with endometrioid cancer whose tumor mismatch repair status was classified by a universal screening program. Associations between epigenetic MMRd, race, other patient characteristics, tumor grade, and stage were assessed using multivariate regression.
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
Acta Neuropathol
February 2025
Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.
Pediatric high-grade glioma (pedHGG) can occur as first manifestation of cancer predisposition syndromes resulting from pathogenic germline variants in the DNA mismatch repair (MMR) genes MSH2, MSH6, MLH1, and PMS2. The aim of this study was to establish a generalized screening for Lynch syndrome and constitutional MMR deficiency (CMMRD) in pedHGG patients, as the detection of MMR deficiencies (MMRD) may enable the upfront therapeutic use of checkpoint inhibitors and identification of variant carriers in the patients' families. We prospectively enrolled 155 centrally reviewed primary pedHGG patients for MMR-immunohistochemistry (IHC) as part of the HIT-HGG-2013 trial protocol.
View Article and Find Full Text PDF